## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 90 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (90).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($98.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-28 | Stifel | $105 | $80 | +31% |
| 2025-11-25 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-24 | Benchmark | $0 | $0 | 0% |
| 2025-11-24 | Jefferies | $105 | $90 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-28 | Stifel | down | Hold |
| 2025-11-25 | Canaccord Genui | down | Hold |
| 2025-11-24 | Benchmark | down | Hold |
| 2025-11-24 | Jefferies | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Overbought RSI (90) with bearish MACD signals exhaustion.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +26%) could attract flows.
- Momentum building: MRS_10 improving +2.9% over 5 days suggests accumulation.

### Fundamentals

Forward P/E 91.0x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Analyst sentiment positive (5 raises, avg +26%). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $101.95 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 91.0 |
| Current P/E | 300.9 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -0.7% to 2.2% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.00), momentum weakening. RSI overbought at 90, risk of mean reversion. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.20% (CS: 51) | Neutral |
| RSI_14 | 89.7 | Overbought |
| MACD Histogram | -1.00 | Bearish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.321x | Above |
| vs SMA200 | 1.796x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.74
- **Stop Loss:** $98.52 (3.2% risk)
- **Target:** $104.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 372
- **Position Value:** $37,847.28
- **Portfolio %:** 37.85%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*